Publication | Closed Access

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Ezh2 Inhibitor TazemetostatMalignant DiseaseMedicineImmunologyPathologyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer Research